Genmab A/S Announces Grant of Restricted Stock Units and Warrants to Employees

On June 11, 2026, Genmab A/S announced that its Board of Directors approved the grant of 15,894 restricted stock units (RSUs) and 15,494 warrants to employees of the company and its subsidiaries. Each RSU represents a conditional right to receive one share of Genmab A/S (nominally DKK 1) at no cost, with a fair value of DKK 1,616.50 based on the closing market price on the date of grant. These RSUs are scheduled to vest after a three-year period. The granted warrants carry an exercise price of DKK 1,616.50 per share. Using the Black-Scholes formula, the fair value of each warrant is calculated at DKK 534.23. The warrants will vest three years from the grant date and are set to expire on the seventh anniversary of the grant. These incentive awards were issued under the terms of the company's established RSU and warrant programs to align employee interests with shareholder value. Genmab is a biotechnology firm specializing in antibody medicines for cancer and other serious diseases.